Table 3.
Geometric mean titers (1:) and 95% confidence intervals
| H1N1 |
H3N2 |
B |
||||
|---|---|---|---|---|---|---|
| Variable | Baseline | Post-vaccination | Baseline | Post-vaccination | Baseline | Post–vaccination |
| Age (y) | ||||||
| <65 | 21.2 (14.3–31.3) | 248.1 (184.2–334.1) | 14.9 (10.7–20.7) | 184.3 (134.2–253.2) | 43.5 (35.4–53.5)b | 244.6 (186.9–320.1)c |
| ≥65 | 16.2 (10.3–25.4) | 292.8 (207.1–414.0) | 9.5 (6.9–13.0) | 198.0 (141.7–276.8) | 21.5 (15.3–30.1) | 157.2 (122.4–201.8) |
| Gender | ||||||
| Male | 18.2 (12.8–25.7) | 266.9 (202.3–352.2) | 10.9 (8.2–14.5) | 183.8 (138.9–243.2) | 28.7 (22.4–36.9)d | 200.2 (160.1–250.2) |
| Female | 20.6 (11.6–36.6) | 267.1 (185.6–384.3) | 16.7 (11.3–24.5) | 209.9 (143.4–307.1) | 42.5 (32.0–56.5) | 203.6 (139.4–297.5) |
| Severity of disease | ||||||
| Mild and moderate | 15.0 (10.9–20.6)a | 245.3 (184.0–327.1) | 12.0 (9.2–15.7) | 199.3 (150.5–263.8) | 30.3 (23.7–38.8) | 211.1 (165.6–269.1) |
| Severe | 30.5 (16.6–55.8) | 320.0 (227.1–451.0) | 12.5 (7.6–20.4) | 172.3 (115.2–257.8) | 35.3 (24.9–50.2) | 181.1 (133.9–244.9) |
| Comorbidities | ||||||
| Yes | 16.0 (10.5–24.3) | 247.3 (176.2–347.0) | 14.0 (9.9–19.8) | 182.0 (127.6–259.7) | 26.7 (18.9–37.9) | 197.3 (146.7–265.4) |
| No | 21.9 (14.5–33.2) | 287.3 (212.6–388.2) | 10.6 (7.7–14.7) | 198.5 (147.5–267.2) | 37.6 (30.7–46.1) | 204.7 (159.8–262.3) |
| Total | 18.8 (14.0–25.1) | 267.0 (213.8–333.4) | 12.2 (9.6–15.4) | 190.3 (151.7–238.6) | 31.8 (26.1–38.8) | 201.1 (166.5–242.8) |
Note: a: P = 0.02; b: P = 0.0006; c: P = 0.02; d: P = 0.04. The GMT for influenza virus H1N1 was highest post-vaccination (F = 3.51, P = 0.03).